Brokerages Expect Stemline Therapeutics Inc (NASDAQ:STML) to Post -$0.34 Earnings Per Share

Equities research analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to report earnings per share (EPS) of ($0.34) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.63) to $0.00. Stemline Therapeutics reported earnings per share of ($0.92) during the same quarter last year, which indicates a positive year over year growth rate of 63%. The company is expected to issue its next earnings report on Friday, March 20th.

On average, analysts expect that Stemline Therapeutics will report full year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($2.16) to ($1.43). For the next financial year, analysts forecast that the firm will report earnings of ($0.49) per share, with EPS estimates ranging from ($1.36) to $0.53. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. The business had revenue of $13.33 million for the quarter, compared to analyst estimates of $13.40 million.

A number of equities analysts have weighed in on the company. Zacks Investment Research lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research note on Wednesday, September 18th. BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Alliance Global Partners initiated coverage on Stemline Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $21.00 target price on the stock. Finally, ValuEngine cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.57.

STML traded down $0.20 during midday trading on Wednesday, hitting $9.74. 406,187 shares of the company were exchanged, compared to its average volume of 613,687. The company’s 50 day simple moving average is $10.14 and its 200 day simple moving average is $12.19. The firm has a market capitalization of $498.28 million, a price-to-earnings ratio of -3.26 and a beta of 1.38. Stemline Therapeutics has a 1-year low of $7.82 and a 1-year high of $18.22.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhenman & Partners Asset Management AB grew its position in Stemline Therapeutics by 3.4% during the third quarter. Rhenman & Partners Asset Management AB now owns 511,023 shares of the biopharmaceutical company’s stock valued at $5,320,000 after buying an additional 17,024 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Stemline Therapeutics by 51.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,297 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 1,466 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Stemline Therapeutics by 14.0% during the second quarter. Vanguard Group Inc. now owns 1,933,455 shares of the biopharmaceutical company’s stock valued at $29,620,000 after acquiring an additional 237,768 shares during the last quarter. Empire Life Investments Inc. raised its holdings in shares of Stemline Therapeutics by 52.8% during the third quarter. Empire Life Investments Inc. now owns 514,269 shares of the biopharmaceutical company’s stock valued at $5,354,000 after acquiring an additional 177,645 shares during the last quarter. Finally, C WorldWide Group Holding A S lifted its position in shares of Stemline Therapeutics by 16.4% in the third quarter. C WorldWide Group Holding A S now owns 998,677 shares of the biopharmaceutical company’s stock valued at $10,396,000 after acquiring an additional 140,595 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Story: Does the discount rate affect the economy?

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.